AnnJi Pharmaceutical überführt AJ201 in die zulassungsrelevante Phase-3-Studie „ROMA-KD" zur Behandlung der spinalen und bulbären Muskelatrophie (SBMA)

Phase 3AJ201Positive

AI Analysis

Summary

AnnJi Pharmaceutical advances AJ201 (Rosolutamid) into Phase 3 ROMA-KD trial for treatment of spinal and bulbar muscular atrophy (SBMA), the only known clinical Phase 3 therapy in development for this indication.

Clinical Trial Data

Phase

Phase 3

Importance:7/10

Sentiment:

0.60

Phase 3Clinical TrialSBMARosolutamidROMA-KD

Read the original article

Published by PR Newswire Pharma on October 6, 2026 1:51 AM

Read Original